Wellington Management Group LLP Has $572.79 Million Stake in Option Care Health, Inc. $OPCH

Key Points

• Wellington Management Group LLP reduced its holdings in Option Care Health by 10.6%, selling over 1.9 million shares during the first quarter, retaining approximately 10.01% of the company valued at $572.8 million.
• Despite Wellington's reduction, other institutional investors like Brooklyn Investment Group and Bessemer Group Inc. increased their stakes significantly, indicating ongoing interest in Option Care Health.
• Analysts have a positive outlook on Option Care Health, with several upgrades and a consensus rating of "Moderate Buy", and an average target price of $35.75.

Wellington Management Group LLP lessened its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 10.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,388,762 shares of the company's stock after selling 1,936,361 shares during the quarter. Wellington Management Group LLP owned about 10.01% of Option Care Health worth $572,787,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of OPCH. Dimensional Fund Advisors LP grew its position in shares of Option Care Health by 17.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after purchasing an additional 591,042 shares during the period. Northern Trust Corp grew its position in shares of Option Care Health by 11.8% in the 4th quarter. Northern Trust Corp now owns 2,626,478 shares of the company's stock valued at $60,934,000 after purchasing an additional 278,158 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Option Care Health by 4.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,609,705 shares of the company's stock valued at $91,209,000 after purchasing an additional 99,574 shares during the period. Nuveen LLC bought a new position in shares of Option Care Health during the first quarter worth about $70,965,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Option Care Health by 6,525,926.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock worth $52,459,000 after buying an additional 1,500,963 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors.

Insider Activity at Option Care Health

In other Option Care Health news, Director Timothy P. Sullivan acquired 20,000 shares of the business's stock in a transaction dated Thursday, August 21st. The stock was bought at an average cost of $27.51 per share, with a total value of $550,200.00. Following the completion of the transaction, the director directly owned 49,229 shares in the company, valued at approximately $1,354,289.79. This represents a 68.43% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the business's stock in a transaction dated Wednesday, August 20th. The stock was acquired at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the transaction, the director owned 375,390 shares of the company's stock, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JMP Securities increased their price objective on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a report on Thursday, July 31st. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. UBS Group upgraded Option Care Health from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. Finally, Barrington Research reiterated an "outperform" rating and set a $38.00 price objective on shares of Option Care Health in a report on Thursday, July 10th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Option Care Health Stock Up 3.2%

NASDAQ OPCH traded up $0.90 during trading hours on Friday, hitting $28.74. 2,369,675 shares of the company traded hands, compared to its average volume of 1,997,394. The business's 50-day moving average is $29.92 and its 200-day moving average is $31.76. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.00 and a current ratio of 1.52. The stock has a market capitalization of $4.66 billion, a price-to-earnings ratio of 22.99, a P/E/G ratio of 1.75 and a beta of 0.79.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.40 by $0.01. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The firm had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.35 billion. During the same period in the prior year, the firm posted $0.30 earnings per share. The business's quarterly revenue was up 15.4% compared to the same quarter last year. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.